JP7066632B2 - 親油性抗炎症剤を含む脂質ナノ粒子およびその使用方法 - Google Patents

親油性抗炎症剤を含む脂質ナノ粒子およびその使用方法 Download PDF

Info

Publication number
JP7066632B2
JP7066632B2 JP2018558293A JP2018558293A JP7066632B2 JP 7066632 B2 JP7066632 B2 JP 7066632B2 JP 2018558293 A JP2018558293 A JP 2018558293A JP 2018558293 A JP2018558293 A JP 2018558293A JP 7066632 B2 JP7066632 B2 JP 7066632B2
Authority
JP
Japan
Prior art keywords
inflammatory
lipid
lofleponide
pharmaceutical composition
budesonide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018558293A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019514979A (ja
JP2019514979A5 (enExample
Inventor
レンナルト・リンドフォーシュ
トマス・シェルマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2019514979A publication Critical patent/JP2019514979A/ja
Publication of JP2019514979A5 publication Critical patent/JP2019514979A5/ja
Priority to JP2021212753A priority Critical patent/JP2022058438A/ja
Application granted granted Critical
Publication of JP7066632B2 publication Critical patent/JP7066632B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018558293A 2016-05-09 2017-05-08 親油性抗炎症剤を含む脂質ナノ粒子およびその使用方法 Active JP7066632B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021212753A JP2022058438A (ja) 2016-05-09 2021-12-27 親油性抗炎症剤を含む脂質ナノ粒子およびその使用方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662333574P 2016-05-09 2016-05-09
US62/333,574 2016-05-09
US201662359429P 2016-07-07 2016-07-07
US62/359,429 2016-07-07
US201762449623P 2017-01-24 2017-01-24
US62/449,623 2017-01-24
PCT/EP2017/060891 WO2017194454A1 (en) 2016-05-09 2017-05-08 Lipid nanoparticles comprising lipophilic anti-inflammatory agents and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021212753A Division JP2022058438A (ja) 2016-05-09 2021-12-27 親油性抗炎症剤を含む脂質ナノ粒子およびその使用方法

Publications (3)

Publication Number Publication Date
JP2019514979A JP2019514979A (ja) 2019-06-06
JP2019514979A5 JP2019514979A5 (enExample) 2020-06-18
JP7066632B2 true JP7066632B2 (ja) 2022-05-13

Family

ID=58671696

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018558293A Active JP7066632B2 (ja) 2016-05-09 2017-05-08 親油性抗炎症剤を含む脂質ナノ粒子およびその使用方法
JP2021212753A Withdrawn JP2022058438A (ja) 2016-05-09 2021-12-27 親油性抗炎症剤を含む脂質ナノ粒子およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021212753A Withdrawn JP2022058438A (ja) 2016-05-09 2021-12-27 親油性抗炎症剤を含む脂質ナノ粒子およびその使用方法

Country Status (6)

Country Link
US (2) US11458106B2 (enExample)
EP (1) EP3454835B1 (enExample)
JP (2) JP7066632B2 (enExample)
CN (1) CN109152735B (enExample)
ES (1) ES2871537T3 (enExample)
WO (1) WO2017194454A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL316479A (en) 2014-06-25 2024-12-01 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle compositions for nucleic acid delivery
HUE067372T2 (hu) 2015-06-29 2024-10-28 Acuitas Therapeutics Inc Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására
RS63986B1 (sr) 2015-10-28 2023-03-31 Acuitas Therapeutics Inc Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
US11458106B2 (en) 2016-05-09 2022-10-04 Astrazeneca Ab Lipid nanoparticles comprising lipophilic anti-inflammatory agents and methods of use thereof
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
EP4714454A2 (en) * 2016-10-26 2026-03-25 Acuitas Therapeutics Inc. Lipid nanoparticle formulations
WO2018191657A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
ES2981244T3 (es) 2017-04-28 2024-10-07 Acuitas Therapeutics Inc Novedosas formulaciones de nanopartículas de lípidos de carbonilo y lípidos para la administración de ácidos nucleicos
US11639329B2 (en) 2017-08-16 2023-05-02 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
EP4501322A3 (en) 2017-08-17 2025-04-16 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019036030A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
US11542225B2 (en) 2017-08-17 2023-01-03 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
IL281615B2 (en) 2018-09-21 2026-01-01 Acuitas Therapeutics Inc Systems and methods for producing lipid nanoparticles and liposomes
US12583816B2 (en) 2018-10-18 2026-03-24 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
JP7523449B2 (ja) 2019-01-11 2024-07-26 アクイタス セラピューティクス インコーポレイテッド 活性剤の脂質ナノ粒子送達のための脂質
US20220226243A1 (en) * 2019-05-08 2022-07-21 Astrazeneca Ab Methods of using lipid nanoparticles for delivering modified rna encoding a vegf-a polypeptide and pharmaceutical compositions comprising the same
CN110974954B (zh) * 2019-12-24 2021-03-16 珠海丽凡达生物技术有限公司 一种用于增强核酸疫苗免疫效果的脂质纳米颗粒及其制备方法
WO2021148511A1 (en) * 2020-01-21 2021-07-29 Etherna Immunotherapies Nv Lipid nanoparticles
JP7798855B2 (ja) 2020-07-16 2026-01-14 アクイタス セラピューティクス インコーポレイテッド 脂質ナノ粒子に使用するためのカチオン性脂質
US20240301090A1 (en) 2021-07-13 2024-09-12 Technion Research & Development Foundation Limited Compositions and methods for treating a medical condition
IL312599A (en) * 2021-11-05 2024-07-01 G2Gbio Inc Pharmaceutical kit for parenteral co-administration
CA3242402A1 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US20250134825A1 (en) * 2022-02-02 2025-05-01 Mslsolutions Gmbh Method for producing medications and vaccines
CN114617980A (zh) * 2022-03-09 2022-06-14 广州国家实验室 可电离脂质纳米颗粒及其应用
KR20250142871A (ko) * 2023-01-09 2025-09-30 노스밀스, 인크. 결핍제한 면역반응 치료를 위한 miRNA 기반 입자
WO2025215636A1 (en) 2024-04-08 2025-10-16 Yeda Research And Development Co. Ltd. Anti-defense system polypeptides and uses thereof
WO2026009227A1 (en) 2024-07-04 2026-01-08 Yeda Research And Development Co. Ltd. Compositions for downregulating zeb2 in macrophages and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060062841A1 (en) 2004-09-01 2006-03-23 Leaf Huang Liposomal vectors
CN101708338A (zh) 2008-12-26 2010-05-19 中国人民解放军军事医学科学院放射与辐射医学研究所 含甾体结构的前药及其高度分散制剂
JP2012530059A (ja) 2009-06-10 2012-11-29 アルニラム・ファーマシューティカルズ・インコーポレーテッド 改善された脂質製剤
JP2012530143A (ja) 2009-06-15 2012-11-29 アルナイラム ファーマシューティカルズ， インコーポレイテッド Ｐｃｓｋ９遺伝子を標的とする、脂質で製剤化されたｄｓｒｎａ
JP2014508796A (ja) 2011-03-24 2014-04-10 レオ ファーマ アクティーゼルスカブ 脂質ナノ粒子とコルチコステロイドまたはビタミンｄ誘導体とを含む組成物
JP2015501844A (ja) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
JP2015509968A (ja) 2012-03-14 2015-04-02 バイオニア・アクティーゼルスカブＢｉｏｎｅｅｒ Ａ／Ｓ 全血中のヒトｃｄ１４＋単球を特異的に標的化するためのカチオン性リポソーム薬物送達系

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA95160463B1 (ar) * 1994-12-22 2005-10-04 استرا أكتيبولاج مساحيق للاستنشاق
AU2011285909B2 (en) 2010-08-02 2016-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
BR112015027291A8 (pt) 2013-05-03 2019-12-24 Selecta Biosciences Inc uso de um imunossupressor que têm uma vida eficaz farmacodinâmica especificada e composição compreendendo o referido imunossupressor
IL316479A (en) 2014-06-25 2024-12-01 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle compositions for nucleic acid delivery
US11458106B2 (en) 2016-05-09 2022-10-04 Astrazeneca Ab Lipid nanoparticles comprising lipophilic anti-inflammatory agents and methods of use thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060062841A1 (en) 2004-09-01 2006-03-23 Leaf Huang Liposomal vectors
CN101708338A (zh) 2008-12-26 2010-05-19 中国人民解放军军事医学科学院放射与辐射医学研究所 含甾体结构的前药及其高度分散制剂
JP2012530059A (ja) 2009-06-10 2012-11-29 アルニラム・ファーマシューティカルズ・インコーポレーテッド 改善された脂質製剤
JP2012530143A (ja) 2009-06-15 2012-11-29 アルナイラム ファーマシューティカルズ， インコーポレイテッド Ｐｃｓｋ９遺伝子を標的とする、脂質で製剤化されたｄｓｒｎａ
JP2014508796A (ja) 2011-03-24 2014-04-10 レオ ファーマ アクティーゼルスカブ 脂質ナノ粒子とコルチコステロイドまたはビタミンｄ誘導体とを含む組成物
JP2015501844A (ja) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
JP2015509968A (ja) 2012-03-14 2015-04-02 バイオニア・アクティーゼルスカブＢｉｏｎｅｅｒ Ａ／Ｓ 全血中のヒトｃｄ１４＋単球を特異的に標的化するためのカチオン性リポソーム薬物送達系

Also Published As

Publication number Publication date
CN109152735B (zh) 2022-03-11
US11458106B2 (en) 2022-10-04
ES2871537T3 (es) 2021-10-29
EP3454835A1 (en) 2019-03-20
JP2019514979A (ja) 2019-06-06
CN109152735A (zh) 2019-01-04
US20220370370A1 (en) 2022-11-24
JP2022058438A (ja) 2022-04-12
EP3454835B1 (en) 2021-03-31
WO2017194454A1 (en) 2017-11-16
US20170367988A1 (en) 2017-12-28

Similar Documents

Publication Publication Date Title
JP2022058438A (ja) 親油性抗炎症剤を含む脂質ナノ粒子およびその使用方法
JP4885715B2 (ja) イリノテカン製剤
US12109310B2 (en) Exosome extracellular vesicles and methods of use
CN110522918A (zh) 靶向元件及其制备方法和运用
KR20140097276A (ko) 약물 전달을 위한 지질 나노입자 생산 방법
CN118319880B (zh) 靶向肺部高效递送核酸的脂质纳米颗粒、吸入式制剂及应用
JP2024056796A (ja) インビボでの核酸発現のためのシステム及び方法
WO2008052766A2 (en) Cationic colloidal carriers for delivery of active agents to the blood-brain barrier in the course of neuroinflammatory diseases
EP4069305A1 (en) Nanostructured drug delivery system as a multifunctional platform for therapy
JP2006508912A5 (enExample)
Ji et al. Synaptic vesicle-inspired nanoparticles with spatiotemporally controlled release ability as a “nanoguard” for synergistic treatment of synucleinopathies
EP4251598A2 (en) Long-acting and long-circulating delivery vehicles
Song et al. Microenvironments‐targeted nanomaterials for atherosclerosis therapy
WO2026077273A1 (zh) 含LNP和mRNA的组合物及其在治疗戈谢病中的应用
CN1980671B (zh) 含有水难溶性喜树碱的脂质体制剂
Chidambaram et al. Mitochondria-targeted drug delivery in neurodegenerative diseases
CN110898231B (zh) 一种功能化拉洛他赛脂质体及其制备方法与应用
US11234933B1 (en) Surface-modified emulsomes for intranasal delivery of drugs
US20240269248A1 (en) Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
WO2023287751A1 (en) Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia
Mu et al. Decoupling efficacy from toxicity: Inhalable liposomal nintedanib for safe and effective treatment of pulmonary fibrosis
Lee et al. Bile Acid–Histidine Decapeptide Conjugates as Promising Additives in Lipid Nanoparticle Formulation for siRNA Delivery
Bajad et al. Drug Delivery Approaches in the Management of Inflammatory Diseases
Khatoon et al. Targeted biologic therapies and advanced drug delivery approaches in asthma management: a clinical perspective
CN120241640A (zh) 靶向纳米粒组合物及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200507

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210528

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211227

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211227

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220112

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220329

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220427

R150 Certificate of patent or registration of utility model

Ref document number: 7066632

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250